A decade after millions of women went cold turkey on the hormone pills that controlled their hot flashes, mood swings and other menopausal symptoms, some doctors say the therapy is safe to try again. The once-feared hormone therapy is now offered in smaller doses and for a shorter time period, said Dr. Christopher Englert, director of obstetrics and gynecology at Holy Name Medical Center in Teaneck. "More and more women are coming back to it.
Lani Martin went through life "in a coma." The Wyckoff resident had no energy and couldn't focus. She was losing her hair and getting depressed. In her late 40s, Martin was not in menopause yet, but after doing some research, she thought her issues might be hormonal. Blood tests confirmed low hormone levels and she decided to try bioidentical hormone replacement therapy (BHRT). Bioidenticals have identical molecular structure to the hormones produced by the human body. They are derived from plants such as yams and soy. Synthetic hormones, like PremPro, Premarin and Pro-vera, are created from horse urine.
WASHINGTON - Women who are past menopause and healthy should not take hormone replacement therapy in hopes of warding off dementia, bone fractures or heart disease, says a new analysis by the government task force that weighs the risks and benefits of screening and other therapies aimed at preventing illness. The recommendation by the U.S. Preventive Services Task Force does not necessarily apply to women who take hormone replacement therapy to reduce menopausal symptoms such as hot flashes, night sweats and vaginal dryness. The balance of harms and benefits for that use is expected to be addressed in an imminent report by the federal government's Office of Health Quality Research.
DEAR DR. DONOHUE: At age 22, my daughter had surgery for a pituitary tumor, followed by radiation. Her hands and feet swelled considerably. They never returned to their normal size. She is now age 51 and has become a recluse. She says people stare at her hands and feet. She is an emotional wreck and cannot work. She recently felt ill and was seen in the emergency room, where the possibility of adrenal insufficiency was suggested. Her husband died of leukemia at age 31, and she raised two daughters by herself. -- K.S. ANSWER: Your daughter has had more than her share of misfortune. Reconstructing her story, I imagine she had a pituitary tumor (the small gland on the underside of the brain) that produced excessive amounts of growth hormone. That's the reason why her hands and feet grew. T...
With Pfizer and plaintiffs' lawyers squabbling over who has won the most hormone replacement therapy trials, only one thing about the litigation is clear: It's turning into one of the longest- running mass torts in U.S. history. I believe that this is now the longest-running MDL with no inventory settlements and no mass settlements in sight," said Zoe Littlepage, a partner at Littlepage Booth in Houston and lead plaintiffs' counsel in the federal multi-district litigation.
CHICAGO - Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects that have curbed enthusiasm for other prevention drugs, a major study found. It was the first test in healthy women of newer hormone-blocking pills called aromatase inhibitors, sold as Arimidex, Femara and Aromasin, and in generic form. They're used now to prevent recurrences in breast cancer patients who are past menopause, and doctors have long suspected they might help prevent initial cases, too.
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
arms race | Crescent Resources Corp | And Turkey | international finance review | Joe Mokwa | Seguro de explosión | Aereos a salta | definicion tecnologia | natura 2000 basilicata | tattersall comercial s.a
